All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or Myeloma crowd.
During the 8th World Congress on Controversies in Multiple Myeloma (COMy), the Multiple Myeloma Hub was pleased to speak to Ajai Chari, Icahn School of Medicine at Mount Sinai, New York, US. We asked, Which targets are being explored in myeloma with bispecific antibodies?
Which targets are being explored in myeloma with bispecific antibodies?
Chari begins by explaining the benefits of bispecific antibody therapies, such as their "off-the-shelf" use, as well as the potential to use them in patients with comorbidities. Chari goes on to discuss three targets of bispecific antibodies; BCMA, GPRC5D, and FcRH5.
Combining bispecific antibodies with daratumumab to treat relapsed/refractory MM
During the 3rd European Myeloma Network Meeting, the Multiple Myeloma Hub was pleased to speak with María-Victoria Mateos, University Hospital of Salamanca, Salamanca,...
First-in-human study of REGN5458, a novel BCMA bispecific antibody
This article summarizes the updated safety, overall response, and response durability in patients treated in the phase I dose-escalation part of the trial, presented at the 63rd ASH...
Cevostamab for relapsed/refractory multiple myeloma
Cevostamab targets the membrane-proximal domain of Fc receptor homolog 5 (FcRH5), which is expressed exclusively on B-lineage cells. Cevostamab, as an FcRH5/CD3 bispecific antibody, has shown...
Subscribe to get the best content related to multiple myeloma delivered to your inbox